| Mary Kate Camara, PT, DPT | |
|
529 Main St, Acton, MA 01720-3964 | |
| (978) 881-0090 | |
| Not Available |
| Full Name | Mary Kate Camara |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 9 Years |
| Location | 529 Main St, Acton, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902389554 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 21864 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Connections Physical Therapy, Inc. | 3577456623 | 64 |
News Archive
A troubling psychological phenomenon that just about everyone has experienced but few will admit to; having difficulty distinguishing between people of different racial groups.
How do you prepare for a crisis? When does the general public have to be notified of a risk? And how should authorities deal with scientific uncertainty? These questions are being discussed by food safety experts from Germany and Bosnia-Herzegovina in Sarajevo from 22- 26 October 2018 at the practice workshop "Dealing with foodborne disease outbreaks".
Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
Three pharmaceutical executives with extensive experience in dealing with the FDA's Risk Evaluation and Mitigation Strategy (REMS) will share their thoughts and practices at an open industry webinar at 12 noon EST on Wednesday, March 10, sponsored by ParagonRx.
› Verified 3 days ago
| Entity Name | Connections Physical Therapy, Inc. |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1699752931 PECOS PAC ID: 3577456623 Enrollment ID: O20040204000067 |
News Archive
A troubling psychological phenomenon that just about everyone has experienced but few will admit to; having difficulty distinguishing between people of different racial groups.
How do you prepare for a crisis? When does the general public have to be notified of a risk? And how should authorities deal with scientific uncertainty? These questions are being discussed by food safety experts from Germany and Bosnia-Herzegovina in Sarajevo from 22- 26 October 2018 at the practice workshop "Dealing with foodborne disease outbreaks".
Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
Three pharmaceutical executives with extensive experience in dealing with the FDA's Risk Evaluation and Mitigation Strategy (REMS) will share their thoughts and practices at an open industry webinar at 12 noon EST on Wednesday, March 10, sponsored by ParagonRx.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mary Kate Camara, PT, DPT 10 Country Club Dr Apt 1, Manchester, NH 03102-8727 Ph: (774) 644-4253 | Mary Kate Camara, PT, DPT 529 Main St, Acton, MA 01720-3964 Ph: (978) 881-0090 |
News Archive
A troubling psychological phenomenon that just about everyone has experienced but few will admit to; having difficulty distinguishing between people of different racial groups.
How do you prepare for a crisis? When does the general public have to be notified of a risk? And how should authorities deal with scientific uncertainty? These questions are being discussed by food safety experts from Germany and Bosnia-Herzegovina in Sarajevo from 22- 26 October 2018 at the practice workshop "Dealing with foodborne disease outbreaks".
Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
Three pharmaceutical executives with extensive experience in dealing with the FDA's Risk Evaluation and Mitigation Strategy (REMS) will share their thoughts and practices at an open industry webinar at 12 noon EST on Wednesday, March 10, sponsored by ParagonRx.
› Verified 3 days ago
Shweta Sethi, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5 Samantha Way, Acton, MA 01720 Phone: 978-400-8610 | |
Jason Peter Ortolano, PT, DPT Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 340 Great Rd, Acton, MA 01720 Phone: 978-287-6170 Fax: 978-287-1476 |